首页> 外文期刊>Preventive Medicine: An International Journal Devoted to Practice and Theory >Providers' practice, recommendations and beliefs about HPV vaccination and their adherence to guidelines about the use of HPV testing, 2007 to 2010
【24h】

Providers' practice, recommendations and beliefs about HPV vaccination and their adherence to guidelines about the use of HPV testing, 2007 to 2010

机译:2007年至2010年提供商对HPV疫苗接种的实践,建议和信念以及对HPV检测使用准则的遵守情况

获取原文
获取原文并翻译 | 示例
           

摘要

Human papillomavirus (HPV) vaccines prevent cervical pre-cancer lesion and can potentially reduce abnormal Papanicolaou (Pap) results among vaccinated females. However, current U.S. cervical screening guidelines recommend no change in screening initiation and frequency based on vaccination status. We examined providers' practices and beliefs about HPV vaccination to evaluate their adherence to guidelines. We used 4-year data (2007-2010) from two nationally representative samples totaling 2119 primary-care providers from the Cervical Cancer Screening Supplement to the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS). Providers in each survey were stratified to obstetrician/gynecologist (OB/GYNs) and non-OB/GYNs. Descriptive statistics and chi-square tests were performed to assess differences between providers' types in each survey. Approximately 60% of providers believed that HPV vaccination will result in fewer abnormal Pap tests and fewer referrals to colposcopy and over 92% would not change their cervical cancer screening practices for fully vaccinated females. NAMCS OB/GYNs were more likely (p < 0.05) than non-OB/GYNs to rarelyever use the number of sexual partners to determine who gets the HPV vaccine (68.4% vs. 59.1%), more likely to recommend the vaccine to females with history of abnormal Pap (79.6% vs. 68.4%) and to females with a history of HPV positive test result (75.3% vs. 62.8%). Consistent with guidelines, most providers would not change cervical cancer screening practices based on patients' vaccination history. However, some providers used inappropriate tests for making vaccination decisions. Improving HPV vaccine knowledge and recommendations for its use is warranted to implement a successful vaccine program. Published by Elsevier Inc.
机译:人乳头瘤病毒(HPV)疫苗可预防宫颈癌前病变,并可潜在减少接种疫苗的女性中异常的Papanicolaou(Pap)结果。但是,目前的美国子宫颈筛查指南建议,根据疫苗接种状况,筛查的开始时间和频率均应保持不变。我们检查了提供者对HPV疫苗接种的做法和信念,以评估他们对准则的遵守情况。我们使用了两个国家代表性样本的4年数据(2007-2010年),这些样本来自宫颈癌筛查补充资料,国家门诊医疗调查(NAMCS)和国家医院门诊医疗调查(NHAMCS)的2119名初级保健提供者。每次调查的提供者均分为产科医生/妇科医生(OB / GYNs)和非OB / GYNs。进行描述性统计和卡方检验以评估每次调查中提供者类型之间的差异。大约60%的提供者认为,HPV疫苗接种将导致更少的异常Pap检测和更少的阴道镜转诊,并且超过92%的提供者不会改变完全接种疫苗的女性的宫颈癌筛查方法。与非OB / GYN相比,NAMCS OB / GYN更可能(p <0.05)很少/从未使用性伴侣的人数来确定谁接种了HPV疫苗(68.4%vs. 59.1%),更可能推荐该疫苗有异常巴氏病史的女性(79.6%比68.4%)和有HPV阳性检测结果史的女性(75.3%比62.8%)。与指导方针一致,大多数提供者不会根据患者的疫苗接种史改变宫颈癌筛查方法。但是,一些提供者使用了不合适的测试来做出疫苗接种决定。必须提高HPV疫苗知识和使用建议,才能实施成功的疫苗计划。由Elsevier Inc.发布

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号